
## Michel WJM Wouters

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/561456/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nationwide oncological networks for resection of colorectal liver metastases in the Netherlands: Differences and postoperative outcomes. European Journal of Surgical Oncology, 2022, 48, 435-448.	0.5	7
2	Patient-Related Prognostic Factors for Anastomotic Leakage, Major Complications, and Short-Term Mortality Following Esophagectomy for Cancer: A Systematic Review and Meta-Analyses. Annals of Surgical Oncology, 2022, 29, 1358-1373.	0.7	28
3	The unfavorable effects of <scp>COVID</scp> â€19 on Dutch advanced melanoma care. International Journal of Cancer, 2022, 150, 816-824.	2.3	18
4	Outcome after treatment for sebaceous carcinoma: A multicenter study. Journal of Surgical Oncology, 2022, 125, 730-735.	0.8	8
5	Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. JAMA Surgery, 2022, 157, 335.	2.2	20
6	Visualization formats of patient-reported outcome measures in clinical practice: a systematic review about preferences and interpretation accuracy. Journal of Patient-Reported Outcomes, 2022, 6, 18.	0.9	10
7	Conventional regression analysis and machine learning in prediction of anastomotic leakage and pulmonary complications after esophagogastric cancer surgery. Journal of Surgical Oncology, 2022, 126, 490-501.	0.8	7
8	Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2022, 175, 103705.	2.0	3
9	Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nature Medicine, 2022, 28, 1178-1188.	15.2	121
10	Management of checkpoint inhibitor toxicity and survival in patients with advanced melanoma Journal of Clinical Oncology, 2022, 40, 9546-9546.	0.8	0
11	Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors. Melanoma Research, 2022, 32, 460-468.	0.6	7
12	Medication Use and Clinical Outcomes by the Dutch Institute for Clinical Auditing Medicines Program: Quantitative Analysis. Journal of Medical Internet Research, 2022, 24, e33446.	2.1	0
13	A preoperative prediction model for anastomotic leakage after rectal cancer resection based on 13.175 patients. European Journal of Surgical Oncology, 2022, 48, 2495-2501.	0.5	6
14	Adjuvant treatment of in-transit melanoma: Addressing the knowledge gap left by clinical trials Journal of Clinical Oncology, 2022, 40, 9577-9577.	0.8	0
15	Textbook outcome as a composite outcome measure in non-small-cell lung cancer surgery. European Journal of Cardio-thoracic Surgery, 2021, 59, 92-99.	0.6	39
16	T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model. Cancer Immunology, Immunotherapy, 2021, 70, 2291-2300.	2.0	16
17	Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. Hepatology International, 2021, 15, 510-519.	1.9	14
18	Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR. Annals of Surgery, 2021, 274, 383-389.	2.1	28

## MICHEL W J M WOUTERS

#	Article	IF	CITATIONS
19	Predictors of 30-Day Mortality Among Dutch Patients Undergoing Colorectal Cancer Surgery, 2011-2016. JAMA Network Open, 2021, 4, e217737.	2.8	37
20	The prognostic value of the interferon-gamma (IFNγ) signature in patients with macroscopic stage III melanoma treated with and without adjuvant systemic therapy Journal of Clinical Oncology, 2021, 39, 9579-9579.	0.8	5
21	Is adjuvant treatment for melanoma in clinical practice comparable to trials? The first population-based results Journal of Clinical Oncology, 2021, 39, e21523-e21523.	0.8	0
22	Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nationwide quality assurance in the Netherlands Journal of Clinical Oncology, 2021, 39, e18641-e18641.	0.8	0
23	Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. Annals of Internal Medicine, 2021, 174, 641-648.	2.0	46
24	Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. European Journal of Cancer, 2021, 148, 51-57.	1.3	16
25	<i>BRAF</i> and <i>NRAS</i> mutation status and response to checkpoint inhibition in advanced melanoma Journal of Clinical Oncology, 2021, 39, 9558-9558.	0.8	Ο
26	Toxicity, response, and survival in older adults with metastatic melanoma treated with checkpoint inhibitors Journal of Clinical Oncology, 2021, 39, 9544-9544.	0.8	0
27	Dutch advanced melanoma care in times of COVID-19 Journal of Clinical Oncology, 2021, 39, e21502-e21502.	0.8	1
28	Efficacy of checkpoint inhibition in advanced acral melanoma Journal of Clinical Oncology, 2021, 39, e21527-e21527.	0.8	0
29	Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. Cancers, 2021, 13, 2826.	1.7	11
30	Completeness of lymph node dissection in patients undergoing minimally invasive- or open surgery for non-small cell lung cancer: A nationwide study. European Journal of Surgical Oncology, 2021, 47, 1784-1790.	0.5	5
31	Preoperative risk factors for major postoperative complications after complex gastrointestinal cancer surgery: A systematic review. European Journal of Surgical Oncology, 2021, 47, 3049-3058.	0.5	19
32	Variation in incidence, prevention and treatment of persistent air leak after lung cancer surgery. European Journal of Cardio-thoracic Surgery, 2021, 61, 110-117.	0.6	12
33	Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study. Cancers, 2021, 13, 4639.	1.7	9
34	ASO Visual Abstract: Patient-Related Prognostic Factors for Anastomotic Leakage, Major Complications, and Short-Term Mortality Following Esophagectomy for Cancer: A Systematic Review and Meta-Analyses. Annals of Surgical Oncology, 2021, 28, 740-741.	0.7	1
35	Adjuvant treatment for melanoma in clinical practice – Trial versus reality. European Journal of Cancer, 2021, 158, 234-245.	1.3	12
36	Hospital Variation in Cancer Treatments and Survival OutComes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands. Cancers, 2021, 13, 5077.	1.7	1

#	Article	IF	CITATIONS
37	Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases. Melanoma Research, 2021, 31, 58-66.	0.6	6
38	Nationwide analysis of hospital variation in preoperative radiotherapy use for rectal cancer following guideline revision. European Journal of Surgical Oncology, 2020, 46, 486-494.	0.5	14
39	Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma; A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response. Cancers, 2020, 12, 2072.	1.7	16
40	The use of FDGâ€PET/CT to detect early recurrence after resection of highâ€risk stage III melanoma. Journal of Surgical Oncology, 2020, 122, 1328-1336.	0.8	4
41	Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study. Journal of Immunotherapy, 2020, 43, 256-264.	1.2	17
42	Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. Cancers, 2020, 12, 1176.	1.7	11
43	Realâ€world outcomes of advanced melanoma patients not represented in phase <scp>III</scp> trials. International Journal of Cancer, 2020, 147, 3461-3470.	2.3	27
44	Identifying best performing hospitals in colorectal cancer care; is it possible?. European Journal of Surgical Oncology, 2020, 46, 1144-1150.	0.5	13
45	The Dutch Institute for Clinical Auditing. Annals of Surgery, 2020, 271, 627-631.	2.1	49
46	Challenges in sentinel node pathology in the era of adjuvant treatment. Journal of Surgical Oncology, 2020, 122, 964-972.	0.8	7
47	Dutch Gastrointestinal Endoscopy Audit: automated extraction of colonoscopy data for quality assessment and improvement. Gastrointestinal Endoscopy, 2020, 92, 154-162.e1.	0.5	16
48	Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. Cancers, 2020, 12, 1003.	1.7	15
49	565â€Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the dutch gynecological oncology audit (DGOA). , 2020, , .		0
50	High response rates for Tâ€VEC in early metastatic melanoma (stage IIIB/Câ€IVM1a). International Journal of Cancer, 2019, 145, 974-978.	2.3	67
51	Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?. Cancers, 2019, 11, 1940.	1.7	29
52	A National Cohort Study Evaluating the Association Between Short-term Outcomes and Long-term Survival After Esophageal and Gastric Cancer Surgery. Annals of Surgery, 2019, 270, 868-876.	2.1	71
53	ECCO essential requirements for quality cancer care: Melanoma. Critical Reviews in Oncology/Hematology, 2018, 122, 164-178.	2.0	41
54	Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. Anti-Cancer Drugs, 2018, 29, 579-588.	0.7	11

MICHEL W J M WOUTERS

#	Article	IF	CITATIONS
55	ECCO essential requirements for quality cancer care for melanoma: Defining how to organise care. European Journal of Surgical Oncology, 2018, 44, 381-382.	0.5	2
56	National quality registries: how to improve the quality of data?. Journal of Thoracic Disease, 2018, 10, S3490-S3499.	0.6	31
57	Different Risk Factors for Early and Late Colorectal Anastomotic Leakage in a Nationwide Audit. Diseases of the Colon and Rectum, 2018, 61, 1258-1266.	0.7	145
58	Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy. British Journal of Cancer, 2018, 119, 429-434.	2.9	9
59	Achievements in colorectal cancer care during 8 years of auditing in The Netherlands. European Journal of Surgical Oncology, 2018, 44, 1361-1370.	0.5	47
60	PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study. Melanoma Research, 2017, 27, 251-257.	0.6	16
61	Clinical auditing as an instrument for quality improvement in breast cancer care in the Netherlands: The national NABON Breast Cancer Audit. Journal of Surgical Oncology, 2017, 115, 243-249.	0.8	62
62	Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. European Journal of Cancer, 2017, 72, 156-165.	1.3	77
63	Immediate completion lymph node dissectionÂin stage IIIAÂmelanoma does not provide significant additional staging information beyond EORTC SN tumour burden criteria. European Journal of Cancer, 2017, 87, 212-215.	1.3	22
64	Textbook Outcome. Annals of Surgery, 2017, 266, 898-904.	2.1	69
65	Ambulant monitoring and web-accessible home-based exercise program during outpatient follow-up for resected lung cancer survivors: actual use and feasibility in clinical practice. Journal of Cancer Survivorship, 2017, 11, 720-731.	1.5	28
66	In Reply: Centralization of Upper Gastrointestinal Cancer Care Should Be Dictated by Quality of Care. Annals of Surgical Oncology, 2017, 24, 621-622.	0.7	3
67	Supporting Lung Cancer Patients With an Interactive Patient Portal: Feasibility Study. JMIR Cancer, 2017, 3, e10.	0.9	40
68	Colorectal cancer surgery for obese patients: Financial and clinical outcomes of a Dutch populationâ€based registry. Journal of Surgical Oncology, 2016, 113, 489-495.	0.8	14
69	Reduced 30-Day Mortality After Laparoscopic Colorectal Cancer Surgery. Annals of Surgery, 2016, 264, 135-140.	2.1	66
70	Defining a standard set of patient-centred outcomes for lung cancer. European Respiratory Journal, 2016, 48, 852-860.	3.1	88
71	Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survival. European Journal of Cancer, 2016, 67, 164-173.	1.3	30
72	Co-creation of an ICT-supported cancer rehabilitation application for resected lung cancer survivors: design and evaluation. BMC Health Services Research, 2016, 16, 155.	0.9	50

MICHEL WJM WOUTERS

#	Article	IF	CITATIONS
73	eHealth for Breast Cancer Survivors: Use, Feasibility and Impact of an Interactive Portal. JMIR Cancer, 2016, 2, e3.	0.9	65
74	Development of an instrument to analyze organizational characteristics in multidisciplinary care pathways; the case of colorectal cancer. BMC Research Notes, 2015, 8, 134.	0.6	4
75	An interactive portal to empower cancer survivors: a qualitative study on user expectations. Supportive Care in Cancer, 2015, 23, 2535-2542.	1.0	45
76	Optimal Treatment Strategy in Rectal Cancer Surgery: Should We Be Cowboys or Chickens?. Annals of Surgical Oncology, 2015, 22, 3582-3589.	0.7	33
77	An epidemiological evaluation of salivary gland cancer in the Netherlands (1989–2010). Cancer Epidemiology, 2015, 39, 14-20.	0.8	32
78	Empowerment of Cancer Survivors Through Information Technology: An Integrative Review. Journal of Medical Internet Research, 2015, 17, e270.	2.1	96
79	Development of MijnAVL, an Interactive Portal to Empower Breast and Lung Cancer Survivors: An Iterative, Multi-Stakeholder Approach. JMIR Research Protocols, 2015, 4, e14.	0.5	26
80	Centralization of Esophagectomy: How Far Should We Go?. Annals of Surgical Oncology, 2014, 21, 4068-4074.	0.7	59
81	Synchronous Colorectal Carcinoma. Diseases of the Colon and Rectum, 2014, 57, 460-466.	0.7	43
82	Volume criteria for the treatment of head and neck cancer: Are they evidence based?. Head and Neck, 2014, 36, 760-762.	0.9	6
83	Safety of elective colorectal cancer surgery: Nonâ€surgical complications and colectomies are targets for quality improvement. Journal of Surgical Oncology, 2014, 109, 567-573.	0.8	32
84	Impact of hospital volume on breast cancer outcome: a population-based study in the Netherlands. Breast Cancer Research and Treatment, 2014, 147, 177-184.	1.1	14
85	A Combined Measure of Procedural Volume and Outcome to Assess Hospital Quality of Colorectal Cancer Surgery, a Secondary Analysis of Clinical Audit Data. PLoS ONE, 2014, 9, e88737.	1.1	12
86	Quality of Care Indicators for the Surgical Treatment of Gastric Cancer: A Systematic Review. Annals of Surgical Oncology, 2013, 20, 381-398.	0.7	28
87	Evaluating the validity of quality indicators for colorectal cancer care. Journal of Surgical Oncology, 2013, 108, 465-471.	0.8	25
88	Successful and Safe Introduction of Laparoscopic Colorectal Cancer Surgery in Dutch Hospitals. Annals of Surgery, 2013, 257, 916-921.	2.1	73
89	The Relationship Between Volume or Surgeon Specialty and Outcome in the Surgical Treatment of Lung Cancer: A Systematic Review and Meta-Analysis. Journal of Thoracic Oncology, 2012, 7, 1170-1178.	0.5	119
90	Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. European Journal of Cancer, 2012, 48, 1624-1632.	1.3	113

#	Article	IF	CITATIONS
91	Effect of hospital volume on postoperative mortality and survival after oesophageal and gastric cancer surgery in the Netherlands between 1989 and 2009. European Journal of Cancer, 2012, 48, 1004-1013.	1.3	134
92	Improved guideline compliance after a 3â€year audit of multidisciplinary colorectal cancer care in the western part of the Netherlands. Journal of Surgical Oncology, 2012, 106, 1-9.	0.8	10
93	The volumeâ€outcome relation in the surgical treatment of esophageal cancer. Cancer, 2012, 118, 1754-1763.	2.0	139
94	Utility of FDG PET/CT and Brain MRI in Melanoma Patients with Increased Serum S-100B Level During Follow-up. Annals of Surgical Oncology, 2010, 17, 1657-1661.	0.7	34
95	Nationwide outcome registrations to improve quality of care in rectal surgery. An initiative of the European society of surgical oncology. Journal of Surgical Oncology, 2009, 99, 491-496.	0.8	34